Latest Close
₹9,664.00
+1.67%
Connecting…
Day Range
-
Full OHLC pending
Volume
-
Full session data pending
50 DMA
₹8,935.63
200 DMA
₹7,083.45
1 year gain / loss
+₹3,009.00(+45.21%)
₹6,655.00 → ₹9,664.00· 2025-10-30 to 2026-10-30
Charting by TradingView
This stock does not satisfy the default swing-support rules at the selected chart endpoint. Its price, volume and moving averages remain available for manual research.
Snapshot 2026-11-01 · Financial period Jun 2026 · Consolidated figures where available
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
Market Cap
₹2,57,902.73 Cr
P/E
88.17×
Sector -38.72× · above
P/B
15.39×
Sector 4.11× · above
EV / EBITDA
58.97×
Sector 22.21× · above
ROE
15.32%
Sector 0.31%
ROCE
19.56%
Sector 6.48%
ROA
14.60%
Sector -17.12%
Cash Flow / Profit
1.07×
| Period | Revenue | Operating profit | Net profit |
|---|---|---|---|
| Jun 2026 | 3,144 +5.3% | 1,180 | 902 +20.1% |
| Mar 2026 | 2,986 +10.9% | 963 | 751 +28.8% |
| Dec 2025 | 2,692 -5.9% | 780 | 583 -15.4% |
| Sep 2025 | 2,860 | 912 | 689 |
Dividend
24 Jul 2026 · ₹30